ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.
ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.
Diseases develop gradually over years, sometimes decades, before symptoms appear, and are due to malfunctioning physiological processes brought about by our genes and environment. In research published in the journal Proceedings of the National Academy of Sciences (PNAS), ISB researchers have shown how an individual’s genetic risk for disease is often reflected in their blood.
There is a dichotomy between Bacteroides- and Prevotella-dominated guts — two common gut bacterial genera — and there is a significant barrier when it comes to transitioning from one to the other.
In the cellular process of differentiation, information about the concentrations of an important class of proteins residing in a cell’s nucleus has been lacking, a missing link needed for scientists to fully understand how the process works. ISB researchers have quantified this important class of proteins that play a key role in the formation of red blood cells.
Researchers at ISB harnessed deep molecular and physiological information to determine an individual’s biological age, which they found was reflective of overall health compared to chronological age. The findings were published in the Journals of Gerontology: Series A.
ISB, Integrated Diagnostics and Sera Prognostics just announced a paper entitled, “The building blocks of successful translation of proteomics to the clinic,” by Leroy Hood and colleagues published online in Current Opinion in Biotechnology.
Institute for Systems Biology (ISB) is among several organizations conducting a clinical trial testing how health coaching affects the cognitive function of patients with early-stage Alzheimer’s disease and analyzing longitudinal, multi-omic data to explore transitions in cognitive function over time.
Institute for Systems Biology and Arivale “Pioneer 100 Study” Establishes Foundation for New Industry of Scientific Wellness. Personal, dense, dynamic data clouds enable novel insights into mechanisms of wellness and disease, new approaches to biomarker discovery, and the empowerment of individuals to enhance their own health.
NIH Research Matters published an article on our tuberculosis paper. “The incredibly large number of possible drug combinations taken together with the difficulty of growing Mtb in the laboratory make discovery of effective combination therapy extremely challenging,” Dr. Nitin Baliga says. “We hope that our systems-based strategy will accelerate TB drug discovery by helping researchers prioritize combinations that are more likely to be effective.” READ THE ARTICLE
Dr. Leroy Hood to serve as chief science officer for Providence FOR IMMEDIATE RELEASE SEATTLE – March 14, 2016 – With the goal of bringing personalized medicine to every patient, Providence Health & Services and the Institute for Systems Biology announced today an affiliation that will transform health care to a proactive mode that is focused on keeping patients well and identifying the earliest opportunities to reverse or even prevent…